This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Kerr, S. J. Articles by Ruxrungtham, K. Search for Related Content PubMed PubMed Citation Articles by Kerr, S. J. Articles by Ruxrungtham, K. Social Bookmarking                         What's this?

Dyslipidemia in an Asian Population After Treatment for Two Years With Protease Inhibitor-Containing Regimens

The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia, s.kerr{at}unsw.edu.au

Chris Duncombe, MBBS

The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia

Anchalee Avihingsanon, MD

The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand

Jintanat Ananworanich, MD

The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand

Mark Boyd, MBBS, FRACP

The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia, Department of Microbiology and Infectious Diseases, Flinders Medical Centre, Bedford Park, South Australia

Bunruan Sopa

The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand

B. Medtech

Theshinee Chuenyam

The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand

David A. Cooper, MD, DSc

National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia

Joep M.A. Lange, MD, PhD

International Antiviral Therapy Evaluation Center, University of Amsterdam, Amsterdam, the Netherlands

Praphan Phanuphak, MD, PhD

The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Kiat Ruxrungtham, MD, MSc

The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

There are limited data about dyslipidemia in Asian patients treated with combination antiretroviral therapy. To assess the relative association of different protease-inhibitor-containing regimens with the degree of dyslipidemia, fasting lipid levels were compared during 110 weeks in 250 nucleoside-experienced but protease-inhibitor-naïve Thai patients beginning treatment with 5 protease-inhibitor-containing regimens. Regimens were (1) stavudine, didanosine, and saquinavir; (2) zidovudine, lamivudine, and saquinavir; (3) zidovudine, lamivudine, and indinavir; (4) zidovudine, lamivudine, and ritonavir-boosted indinavir; and (5) efavirenz and ritonavir-boosted indinavir. Triglyceride levels were available for all patients; total cholesterol and high-densitylipoprotein cholesterol levels were available for patients receiving indinavir. The strongest predictors of dyslipidemia after beginning protease-inhibitor-based therapy were treatment regimen and baseline dyslipidemia. Triglycerides, total cholesterol, and high-density-lipoprotein cholesterol changes from baseline to week 110 were significant in patients taking ritonavir-boosted indinavir. Efavirenz and ritonavir-boosted indinavir were associated with significant high-density-lipoprotein cholesterol increases compared with other regimens. Non-stavudine-containing non-boosted protease-inhibitor-based highly active antiretroviral treatment regimens had the least association with dyslipidemia.

Key Words: protease inhibitor • highly active antiretroviral therapy • Asian • dyslipidemia • HIV • adverse effects

Journal of the International Association of Physicians in AIDS Care (JIAPAC), Vol. 6, No. 1, 36-46 (2007)
DOI: 10.1177/1545109706295946


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?